Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $32 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and maintained a price target of $32.
August 04, 2023 | 10:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rhythm Pharmaceuticals has received a reiterated 'Buy' rating from Needham analyst Joseph Stringer, with a maintained price target of $32.
The reiterated 'Buy' rating and maintained price target by Needham analyst Joseph Stringer indicates a positive outlook for Rhythm Pharmaceuticals. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100